Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NextCure, Inc. - Common Stock (NQ:NXTC)

6.170 +0.910 (+17.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NextCure, Inc. - Common Stock

< Previous 1 2 3 4 Next >
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
From NextCure
Via GlobeNewswire
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
From NextCure
Via GlobeNewswire
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
From NextCure
Via GlobeNewswire
NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates
 
Via Benzinga
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
From NextCure
Via GlobeNewswire
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
 
Via Benzinga
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
From NextCure
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
NextCure to Present at the JMP Securities Life Sciences Conference
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports Full Year 2022 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present at SVB Securities Global Biopharma Conference
From NextCure
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 89 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
NextCure to Present at Upcoming Investor Conferences
From NextCure
Via GlobeNewswire
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
From NextCure
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 97 companies made new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
From NextCure
Via GlobeNewswire
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
From NextCure
Via GlobeNewswire
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 236 companies set new 52-week lows. 
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
From NextCure
Via GlobeNewswire
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors
From NextCure
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.